What is 3SBio?
Founded in 1993, 3SBio operates as a fully-integrated biotechnology enterprise, maintaining a sophisticated infrastructure that spans research, development, manufacturing, and commercialization. The company has cultivated a diverse portfolio of biopharmaceutical franchises, specifically targeting high-growth therapeutic areas including oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology. By leveraging its headquarters in Liaoning, China, 3SBio has effectively bridged the gap between innovative laboratory research and large-scale clinical application, positioning itself as a critical player in the regional and international medical markets. Its integrated business model allows for seamless transitions from drug discovery to market penetration, ensuring a competitive edge in the rapidly evolving life sciences industry.
How much funding has 3SBio raised?
3SBio has raised a total of $712M across 1 funding round:
Stock Offering
$712M
Stock Issuance/Offering (2015): $712M, investors not publicly disclosed
Key Investors in 3SBio
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for 3SBio?
With the infusion of capital from its recent strategic financing, 3SBio is well-positioned to accelerate its pipeline development and expand its therapeutic reach. The company is expected to prioritize the scaling of its existing biopharmaceutical franchises while exploring potential inorganic growth opportunities to bolster its oncology and metabolic disease portfolios. As the firm navigates the complexities of the modern healthcare environment, the focus will likely remain on enhancing manufacturing efficiencies and deepening its clinical research capabilities. This strategic trajectory suggests a continued emphasis on sustainable growth and the pursuit of high-impact medical breakthroughs that address unmet patient needs across its core therapeutic domains.
See full 3SBio company page
